Utilizing this approach, we showed in mouse models of CRC liver metastases that the local delivery of IFNα by TEMs exerts a potent anti‐tumor activity without inducing systemic side effects or hematopoietic toxicity and without altering the host immune capacity to respond to a virus challenge. The gene discussed is IFNA1; the disease is colorectal carcinoma.